Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

Rando, E., Segala, F. V., Vargas, J., Seguiti, C., De Pascale, G., Murri, R., Fantoni, M., Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy, <<ANTIBIOTICS>>, 2021; 11 (1): 3-7. [doi:10.3390/antibiotics11010003] [https://hdl.handle.net/10807/232153]

Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy

Rando, Emanuele;De Pascale, Gennaro;Murri, Rita;Fantoni, Massimo
2022

Abstract

Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.
2022
Inglese
Rando, E., Segala, F. V., Vargas, J., Seguiti, C., De Pascale, G., Murri, R., Fantoni, M., Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy, <<ANTIBIOTICS>>, 2021; 11 (1): 3-7. [doi:10.3390/antibiotics11010003] [https://hdl.handle.net/10807/232153]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/232153
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact